Q-omics provides the consensus-scored ZPBP2 profile across patient tissues and cancer cell-line models. ZPBP2 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZPBP2 is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, ZPBP2 RNA expression shows 7,859 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, LUSC, and THYM as cancer lineages where ZPBP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZPBP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZPBP2 survival associations across molecular data types. ZPBP2 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZPBP2 RNA expression–survival associations across cancer types. High ZPBP2 expression shows unfavorable associations in UVM and KIRC, but favorable associations in BLCA, LUAD, HNSC and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZPBP2 RNA expression.
This table summarizes ZPBP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZPBP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZPBP2 shows lower tumor expression in LUSC and PRAD and higher tumor expression in ESCA. The LUSC box plot shows higher ZPBP2 RNA expression in normal versus tumor tissue (log2 FC = −0.145, t-test p = .010).
This table shows molecular features associated with ZPBP2 in patient tissues and cancer cell lines. In patient samples, ZPBP2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZPBP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Lymphoma.
